retatrutide phase 2 nejm 2023 obesity trial jastreboff This week's most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist for — A https://t.co/jNL1GNnHPT #Endocrinology Once-Monthly Maridebart Cafraglutide for the
Description
Oh, that that is such a tough one because this is such a big market and we're so early on
This is speculation based on the broader GLP-1 nasal delivery literature, not confirmed data for retatrutide specifically
10.1007/s12350-018-01547-1 88 VegtE.van EerdJ
Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global GLP-1 Analogues market
Now, with this backdrop, consider an unabashaedly allopathic (allopathy is again a term that is mostly used in India) medicine like GLP-1s
